Propanc Biopharma (OTCMKTS:PPCB) Rating Lowered to Hold at ValuEngine

Propanc Biopharma (OTCMKTS:PPCB) was downgraded by equities research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Wednesday, ValuEngine reports.

Propanc Biopharma stock traded down $0.14 during mid-day trading on Wednesday, reaching $0.76. The stock had a trading volume of 12,511 shares, compared to its average volume of 9,505. Propanc Biopharma has a fifty-two week low of $0.06 and a fifty-two week high of $67.00. The stock’s 50-day simple moving average is $1.19 and its 200-day simple moving average is $0.85.

Propanc Biopharma Company Profile



Propanc Biopharma, Inc, a development-stage healthcare company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. The company's lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically.

Further Reading: Support Level

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Propanc Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Propanc Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.